Regenxbio Receives CRL from FDA, NDA for Takeda’s Oveporextin Accepted, ACP Abandons use of “Provider”

WATCH TIME: 4 minutes | Captions are auto-generated and may contain errors.

Welcome to the Neurology News Network. My name is Louie Pasculli. Here’s a look at this week’s top stories in neurology.

We begin with news from the FDA. Re-gen-X-Bio’s biologics license application for clemidsogene lanparvovec or RGX-121 has received a complete response letter from the FDA. The investigational adeno-associated virus vector-based gene therapy is being developed to treat Hunter syndrome. The FDA issued the letter on February 7, 2026, outlining several reasons the product was not approved in its current form. In a statement, Regenxbio President and CEO Curran Simpson addressed the decision saying quote, "This decision is devastating for the families of boys living with this progressive, life-threatening disease.  We are concerned about FDA’s feedback regarding the overall development path and evaluation of the data in the context of the urgent need for this irreversible ultra-rare disease. We remain confident in the quality and volume of evidence demonstrating the long-term potential of RGX-121 to positively change the trajectory of Hunter syndrome.”

More news coming from the FDA, Takada’s new drug application for oveporexton has been accepted and granted priority review. An investigational oral orexin receptor 2 -selective agonist, for the treatment of patients with narcolepsy type 1, oveporexton’s PDUFA date is scheduled for the third quarter of 2026. The NDA is supported by positive data from global phase 3 studies FirstLight and RadiantLight, which showed that oveporexton met all its primary and secondary end points. In a conversation with NeurologyLive, President of R&D at Takeda Andrew Plump, MD, PHD, stated, “Our investigational therapy oveporexton is designed to address the underlying cause of Narcolepsy type 1 by restoring orexin signaling. If approved, oveporexton would offer people living with narcolepsy type 1 and their healthcare providers a new approach to the way we treat this disease."

Wrapping up with linguistic news, the American College of Physicians recently released a policy paper contending that labeling physicians as “providers” is not merely semantic but has ethical implications that erode professional identity, trust, and the physician–patient relationship. Authors traced the term’s expansion from its 1960s Medicare/Medicaid origin, where "providers” denoted entities eligible for reimbursement, to its current use as a catch-all for clinicians. Authors argued this linguistic shift both reflected and accelerated “de-professionalization,” a process by which corporatization, employment models, and market-driven structures impair physicians’ ability to practice according to ethical standards. The ACP recommended abandoning “provider” when referring to physicians, advocating instead for the use of “physician” for doctors and “clinician” or “health care professional” for collective teams. They concluded that preserving ethical practice requires language that foregrounds medicine’s humanistic commitments: relational care, professional judgment, and patient-centered rather than commercially abstracted interactions.

For more direct access to expert insight, head to NeurologyLive.com. Be sure to tune in next week to stay up to date on the latest in neurology. I’m Louie Pasculli thanks for watching Neurology News network.